Stocktoria
ROCKWELL MEDICAL, INC. RMTI
ROCKWELL MEDICAL, INC. (RMTI) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $69.3M at a -7.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.71 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.5 |
| Retained earnings / assets | -7.052 |
| EBIT / assets | -0.082 |
| Equity / liabilities | 1.834 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
| SPRO | Spero Therapeutics, Inc. | 4/9 | -8.9 | 15.3 | +39.2% |
| AYTU | AYTU BIOPHARMA, INC | 4/9 | -8.14 | — | +1.8% |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 3/9 | -1.34 | — | +153.5% |
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
About ROCKWELL MEDICAL, INC.
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. In addition, it offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
FAQ
Is RMTI financially healthy?
ROCKWELL MEDICAL, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does RMTI pay a dividend?
No, ROCKWELL MEDICAL, INC. does not currently pay a dividend.
How profitable is RMTI?
In FY2025, ROCKWELL MEDICAL, INC. had a net margin of -7.7% and a return on equity of -14.4%.
What is the analyst price target for RMTI?
The average Wall-Street price target for ROCKWELL MEDICAL, INC. is $30.00, about 299.5% above the recent price, from 2 analysts.
Is RMTI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ROCKWELL MEDICAL, INC.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.